A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the multiple dose pharmacokinetics (PK) of three gefapixant (AF-219) formulations; to assess the effect of Omeprazole on the multiple dose PK of three gefapixant formulations; and, to assess the safety and tolerability of gefapixant.

Official Title
-----------------
A Study in Healthy Subjects to Assess the Multiple- Dose Pharmacokinetics of Three AF-219 Formulations

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Omeprazole
* Drug: Omeprazole
* Drug: Gefapixant
* Drug: Gefapixant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be informed of the nature of the study and have provided written informed voluntary consent Be able to speak, read, and understand English; Be healthy males or females, of any race, between 18 and 55 years of age, inclusive; Have a body mass index (BMI) >18.5 and <32.0 kg/m2 and weigh 50 - 100 kg; Be in good general health with no clinically relevant abnormalities based on the medical history, physical examination, clinical laboratory evaluations (hematology, clinical chemistry, and urinalysis), and 12-lead electrocardiogram; Be only non-smokers or intermittent (social) smokers for at least 5 years, and able to refrain from smoking (or using nicotine) while in confinement; If a female of child-bearing potential or not post-menopausal, agree to use 2 forms of acceptable birth control; Be able to communicate effectively with the Investigator and other study center personnel and agree to comply with the study procedures and restrictions Exclusion Criteria: Have previously received gefapixant; Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease; Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication; Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hay-fever during the time of the year that dosing will be taking place; History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2-histamine blockers or proton pump inhibitors within 12 months of Screening; QTcB >450 msec in males or >470 msec in females; Known or suspected hypersensitivity or allergic reaction to any of the components of gefapixant or omeprazole capsules; If female, is pregnant or breast feeding, or has a positive pregnancy test pre-dose; Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of the first dose of study drug; Chronic use of any systemic medications (other than allowable oral and implanted contraceptives and with the exception of vitamins taken at standard supplement doses); use of a drug therapy (including herbal preparations, e.g., St. John's wort) known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications [prescription or over-the-counter (OTC)], including antacids, high-dose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug, unless deemed acceptable by the Investigator and Sponsor; Past or current history or evidence of drug or alcohol abuse, regular use of more than 2 units of alcohol per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 40%), use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or pre-dose; Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration; Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody; Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication; Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gefapixant + Omeprazole<br>Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days | Drug: Omeprazole<br>* 20 mg oral capsules administered once daily for 10 days<br>* Other names: Prilosec;Drug: Omeprazole<br>* 40 mg oral capsules administered twice daily for 10 days<br>* Other names: Prilosec;Drug: Gefapixant<br>* Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days<br>* Other names: MK-7264;Drug: Gefapixant<br>* Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days<br>* Other names: MK-7264;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum plasma concentration (Cmax) profiles of three different oral formulations of gefapixant | Plasma gefapixant concentration versus time profiles will be plotted for each subject; similar summary plots will be constructed for each treatment period. Plasma gefapixant PK parameters will be calculated using noncompartmental methods and summarized using descriptive statistics by each treatment. | 12 hours | 
| Maximum plasma concentration (Cmax) profile of gefapixant following administration of Omeprazole | Analysis of variance (ANOVA) will be performed on log normal-transformed Cmax and AUC0-t values to determine the extent of a drug interaction, if any, of Omeprazole on the plasma gefapixant PK parameters | 12 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Volunteers